Influenza
Pipeline by Development Stage
Drug Modality Breakdown
Infectious Diseases is an $11.9B market dominated by HIV and hepatitis C treatments in their peak revenue phases, reflecting a mature but stable therapeutic area.
Key Trends
- HIV antiretroviral dominance: Nucleoside Reverse Transcriptase Inhibitors account for 44% of spending
- Patent cliff pressure: $2.8B in revenue from major products facing LOE between 2027–2031
- High trial velocity: 9,337 active trials indicate sustained pipeline development despite market maturity
Career Verdict
Infectious Diseases offers stable, well-compensated roles with strong commercial demand, but limited growth upside—ideal for risk-averse professionals seeking established franchises rather than high-growth opportunities.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | BIKTARVY (bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate) | Gilead Sciences | $3.2B | 27% | Peak | Stable | 10.5yr |
| 2 | EPCLUSA (velpatasvir and sofosbuvir) | Gilead Sciences | $877M | 7% | Peak | Stable | 8.2yr |
| 3 | TIVICAY (dolutegravir sodium) | GSK | $657M | 6% | Peak | Declining | 4.1yr |
| 4 | TRIUMEQ (abacavir sulfate, dolutegravir sodium, lamivudine) | GSK | $632M | 5% | Peak | Declining | 4.1yr |
| 5 | GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) | Gilead Sciences | $626M | 5% | Peak | Stable | 6.9yr |
Drug Class Breakdown
backbone of HIV treatment, stable demand
hepatitis C treatment, mature market
boosting agents in combination regimens
niche mechanism, limited growth
Career Outlook
StableInfectious Diseases offers predictable career progression and above-average compensation in Commercial roles, supported by 780 current openings and sustained demand from market incumbents. However, patent cliffs affecting $2.8B in near-term revenue (2027–2031) will compress margins and slow hiring after 2028, particularly in Commercial support and field-based roles. The area is best suited for mid-career professionals seeking stability over rapid growth, with limited appeal for early-career scientists pursuing innovation-driven research.
Breaking In
Enter via Commercial or Manufacturing roles at GSK, Sanofi, or Becton Dickinson to build market expertise and commanding salaries ($160K–$237K); avoid pure R&D tracks unless you target specific mechanisms like long-acting injectables.
For Experienced Professionals
Experienced professionals should pursue Market Access, Medical Affairs, or Commercial Leadership roles where patent cliff expertise commands premium compensation; consider consulting or biotech transition if R&D innovation is your priority.
In-Demand Skills
Best For
Hiring Landscape
Infectious Diseases hiring is heavily weighted toward Commercial roles (247 positions, 32% of total), reflecting mature market dynamics focused on market access and brand management. GSK and Becton Dickinson lead hiring (214 and 188 roles), but Gilead Sciences—the market leader by revenue—shows surprisingly low hiring (25 roles), signaling efficiency-driven operations. Salary progression favors Commercial ($275K avg) over R&D ($184K avg), indicating career acceleration through sales and marketing functions.
Top Hiring Companies
By Department
Strong Commercial hiring with premium salaries suggests Infectious Diseases is an excellent landing spot for brand, sales, and market access professionals, but limited R&D hiring indicates reduced innovation investment.
On Market (4)
Approved therapies currently available
Competitive Landscape
63 companies ranked by most advanced pipeline stage
+33 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 496,956 patients across 50 trials
Influenza Immunity Against Pandemic Respiratory Virus
A Study to Compare the Use of Fluconazole as Continuous Therapy Versus Periodic Therapy in HIV-Positive Patients With Recurrent Thrush
Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines
Pooled Analysis of Methodologically Harmonized Pragmatic Randomized Trials of High-Dose vs. Standard-Dose Influenza Vaccine Against Severe Clinical Outcomes
Bone Marrow and Peripheral Blood Immune Responses Study
Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis
Baloxavir Versus Oseltamivir for Nursing Home Influenza Outbreaks
A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
Test-and-treat for Influenza in Homeless Shelters
Pilot of Cohort of Households for Influenza Monitoring and Evaluation in Seattle
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
Response to Live Attenuated Influenza Vaccine in Tonsillar Tissues and Blood
Response to Inactivated Influenza Vaccine in Lymph Tissue and Blood
A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD
Development of Childhood Anti-Influenza Immunity
FLUAD vs. FLUZONE HD Influenza Vaccine in Residents of Long Term Care
Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations
Gene Signatures of Influenza Vaccine Responses in Older Adults
Age and Response to Flu Vaccines
Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years
Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
Immune Response Following Seasonal Influenza Vaccination
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season
Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)
Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity
Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination
ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir
Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers (SLVP032)
Seasonal Influenza Vaccine, Quadrivalent Versus Trivalent in Patients With Advanced Chronic Obstructive Pulmonary Disease
Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children
Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)
Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season
Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers
Comparative Clinical Trial of Efficacy and Safety of Ergoferon Versus Oseltamivir in Treatment of Influenza
Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)
Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults
Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)
Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years
Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine
Efficacy and Safety of Activation Energy Serum (AES) Versus Placebo in Persistent Asthma.
The Immune Response to Influenza Vaccinations in Elderly Individuals
The Immunogenicity and Safety of 2013-2014 Seasonal Trivalent Influenza Vaccine
B-cell Immunity to Influenza (SLVP017)- Year 5, 2013
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 5, 2013
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine
Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
Related Jobs in Infectious Diseases
Pediatric Immunization Specialist - Los Angeles East
Research Associate, Infectious Disease Virology
Pediatric Immunization Specialist - Queens, NY
Vaccines Sales Director - Houston, TX
Vaccine Account Manager - Pittsburgh, PA
【ViiV】Medical Manager
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.